IDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner
The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the European Union to support the development of sensorbased technologies to assess the severity of global functional deficits of patients with different diseases including Huntington's disease in everyday settings. GHI is responsible to conduct the feasibility study in HD and to coordinate the validation study across several European HD centers.
Roche Studie Generation-HD1 stoppt weitere Dosierung
March 22, 2021
Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem...
Read MorePROOF-HD phase III pivotal trial with Pridopidine
September 30, 2020
GHI will shortly start the pivotal phase III trial PROOF-HD with Pridopidine. Several studies...
Read MoreErreichbarkeit während der Umzugsphase
June 22, 2020
Liebe Patienten, Angehörige und Interessenten,
aufgrund des Umzugs sind die...
Read MoreIDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner
December 6, 2019
The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the...
Read More